Antitumor activity of the PI3K δ-sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2 + breast cancer

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Fiascarelli, Alessio
• dc.contributor.author Merlino, Giuseppe
• dc.contributor.author Capano, Stefania
• dc.contributor.author Talucci, Simone
• dc.contributor.author Bisgnano, Diego
• dc.contributor.author Bressan, Alessandro
• dc.contributor.author Bellarosa, Daniela
• dc.contributor.author Carrisi, Corrado
• dc.contributor.author Paoli, Alessandro
• dc.contributor.author Bigioni, Mario
• dc.contributor.author Tunici, Patrizia
• dc.contributor.author Irrissuto, Clelia
• dc.contributor.author Salerno, Massimiliano
• dc.contributor.author Arribas, Joaquín
• dc.contributor.author de Stanchina, Elisa
• dc.contributor.author Scaltriti, Maurizio
• dc.contributor.author Binaschi, Monica
• dc.date.accessioned 2024-05-02T07:13:42Z
• dc.date.available 2024-05-02T07:13:42Z
• dc.date.issued 2023
• dc.description.abstract Purpose Dysregulation of the PI3K pathway is one of the most common events in breast cancer. Here we investigate the activity of the PI3K inhibitor MEN1611 at both molecular and phenotypic levels by dissecting and comparing its profile and efficacy in HER2 + breast cancer models with other PI3K inhibitors. Methods Models with different genetic backgrounds were used to investigate the pharmacological profile of MEN1611 against other PI3K inhibitors. In vitro studies evaluated cell viability, PI3K signaling, and cell death upon treatment with MEN1611. In vivo efficacy of the compound was investigated in cell line- and patient-derived xenografts models. Results Consistent with its biochemical selectivity, MEN1611 demonstrated lower cytotoxic activity in a p110δ-driven cellular model when compared to taselisib, and higher cytotoxic activity in the p110β-driven cellular model when compared to alpelisib. Moreover, MEN1611 selectively decreased the p110α protein levels in PIK3CA mutated breast cancer cells in a concentration- and proteasome-dependent manner. In vivo, MEN1611 monotherapy showed significant and durable antitumor activity in several trastuzumab-resistant PIK3CA-mutant HER2 + PDX models. The combination of trastuzumab and MEN1611 significantly improved the efficacy compared to single agent treatment. Conclusions The profile of MEN1611 and its antitumoral activity suggest an improved profile as compared to pan-inhibitors, which are limited by a less than ideal safety profile, and isoform selective molecules, which may potentially promote development of resistance mechanisms. The compelling antitumor activity in combination with trastuzumab in HER2 + trastuzumab-resistant, PIK3CA mutated breast cancer models is at the basis of the ongoing B-Precise clinical trial (NCT03767335).
• dc.format.mimetype application/pdf
• dc.identifier.citation Fiascarelli A, Merlino G, Capano S, Talucci S, Bisignano D, Bressan A, et al. Antitumor activity of the PI3K δ-sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2 + breast cancer. Breast Cancer Res Treat. 2023 May;199(1):13-23. DOI: 10.1007/s10549-023-06895-2
• dc.identifier.doi http://dx.doi.org/10.1007/s10549-023-06895-2
• dc.identifier.issn 0167-6806
• dc.identifier.uri http://hdl.handle.net/10230/59972
• dc.language.iso eng
• dc.publisher Springer
• dc.relation.ispartof Breast Cancer Res Treat. 2023 May;199(1):13-23
• dc.rights © The Author(s) 2023. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by/4.0/
• dc.subject.keyword MEN1611
• dc.subject.keyword PI3K inhibitor
• dc.subject.keyword PIK3CA mutations
• dc.subject.keyword Patient-derived xenografts
• dc.subject.keyword Trastuzumab resistance
• dc.title Antitumor activity of the PI3K δ-sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2 + breast cancer
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion